Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2564| Título : | Ketorolac pharmacokinetics in experimental cirrhosis by bile duct ligation in the rat |
| Creador: | Rivera Espinosa, Liliana |
| Nivel de acceso: | Open access |
| Palabras clave : | Antiinflamatorios no Esteroideos - farmacocinética Ketorolaco - administración y dosis Ketorolaco -farmacocinética Hígado - Metabolismo Cirrosis Hepática Experimental - Metabolismo gamma-Glutamiltransferasa - metabolismo Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics Ketorolac - administration & dosage Ketorolac - pharmacokinetics Liver - metabolism Liver Cirrhosis, Experimental - metabolism gamma-Glutamyltransferase - metabolism Ketorolaco farmacocinética cirrosis daños en el hígado ligadura del conducto biliar Ketorolac pharmacokinetics cirrhosis liver damage bile duct ligation |
| Descripción : | The purpose of the present work was to study the pharmacokinetics of ketorolac, a poorly metabolized drug, in experimental cirrhosis. Cirrhosis was induced by bile duct ligation (BDL) for four weeks in male Wistar rats. Ketorolac was given intravenously (1 mg/kg ) or orally (3.2 mg/kg) to control (sham-operated) and BDL-rats. Determination of ketorolac in plasma was carried out by HPLC and estimation of pharmacokinetic parameters was performed by non-compartmental analysis. Indicators of liver damage and liver fibrosis were significantly increased (p < 0.05) in BDL compared to control rats. Experimental cirrhosis did not induce any significant alteration in intravenous ketorolac pharmacokinetics. Volume of distribution, clearance, AUC and t1/2 were similar in BDL and control animals. Notwithstanding, oral ketorolac bioavailability was significantly altered in BDL rats. AUC and Cmax were reduced, while tmax was prolonged, suggesting that both, the extent and the rate of ketorolac absorption were decreased. Results show that liver cirrhosis may result in significant pharmacokinetic alterations, even for poorly bio-transformed drugs, but that alterations may vary with the route of administration. In conclusion, uncritical generalizations on the effect of liver damage on drug kinetics should be avoided and systematic studies for every drug and every route of administration are thus recommended |
| Colaborador(es) u otros Autores: | Muriel P Ordaz Gallo M Pérez Urizar J Palma Aguirre A Castañeda Hernández G |
| Fecha de publicación : | 2003 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Fuente: | Ann Hepatol 2(4):175-181 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2564 |
| Idioma: | spa |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.